Navigation Links
CMC Biologics Strengthens its Innovative Biomanufacturing Technology Portfolio in Continuous Perfusion Systems
Date:1/5/2012

COPENHAGEN, Denmark and SEATTLE, Jan. 5, 2012 /PRNewswire/ -- CMC Biologics, a leading biopharmaceutical contract manufacturing organization, announced the issuance of European Patent No. US 2,171,034 B1 covering a method for improving productivity in microbial fermentations and mammalian cell culture bioreactors. The invention is designed to optimize production of a biotherapeutic in a continuous perfusion fermentation process, wherein the bioreactor (fermenter) has an ultrafiltration system that allows impurities to be removed while retaining cells in the bioreactor.

(Logo:  http://photos.prnewswire.com/prnh/20110502/SF93356LOGO)

"CMC Biologics is continually innovating to advance biopharmaceutical manufacturing to the next level. Our expertise in developing efficient production processes puts our clients' projects in an optimal position to succeed," said Mads Laustsen, Chief Scientific Officer of CMC Biologics and Inventor.  "This proprietary technology demonstrates that using the impurity filter improved cell density, productivity and product concentration – all critical to helping our customers move their products to market on time and on target."

 

Perfusion bioreactors involve continuous cell culture, feeding, and withdrawal (harvesting) of product and accumulates no waste products, thereby creating a stable cell growth environment.  Optimal environmental conditions can be precisely controlled with this new technology resulting in increased productivity due to increased cell density in the reactor and in particular, a significant higher concentration of the product in the harvested medium. The expressed biologics are rapidly removed and made available for purification at high concentration — a significant advantage for the downstream processing.

 

About CMC Biologics

CMC Biologics (www.cmcbio.com) is a global contract biopharmaceutical manufacturing and development organization with facilities in Copenhagen, Denmark and Seattle, Washington, USA. CMC Biologics specializes in custom services for scale up and cGMP manufacture of protein-based therapeutics for preclinical, clinical trials, and in-market production. The Company's fully integrated services includes cell line development using its proprietary CHEF1® system, process and formulation development, and comprehensive analytical testing. CMC Biologics has fully segregated microbial fermentation and mammalian cell culture suites and offers stirred tank and perfusion production processes.

 

 


 


'/>"/>
SOURCE CMC Biologics
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. DSM Biologics and MorphoSys AG to Manufacture Fully Human Antibody
2. Cell Therapeutics Submits Supplemental Biologics License Application for Zevalin Use in First-Line Consolidation Therapy
3. Therapure Biopharma Inc. announces collaboration with Induce Biologics Inc.
4. Savient Submits Biologics License Application (BLA) for pegloticase
5. DSM Biologics and Crucell Announce Commercial PER.C6(R) Licensing Agreement with Gedeon Richter
6. Interface Biologics secures $5mm financing and appoints Thomas P. Reeves President and Chief Executive Officer
7. Insmed Sells Follow-on Biologics Platform to Merck & Co., Inc. for Gross Proceeds of $130 Million
8. FDA Accepts Amgens Submission and Files Biologics License Application for Denosumab
9. Bone Biologics Announces UCB-1 (NELL-1) Bone Growth Protein Production Process With Aragen Biosciences
10. Frost & Sullivan Recognizes ApaTechs Leadership in Orthopedic Biologics
11. LaVoie Group Adds Bio-Surgery Company, Pegasus Biologics, to Its Life Sciences Agency Roster
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Prostate Cancer Foundation (PCF) is pleased to announce 24 new Young Investigator ... Members of the Class of 2016 were selected from a pool of 128 ... About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... ... ... STACS DNA Inc., the sample tracking software company, today announced that Dr. ... STACS DNA as a Field Application Specialist. , “I am thrilled that Dr. ... STACS DNA. “In further expanding our capacity as a scientific integrator, Hays brings a ...
(Date:6/23/2016)... LONDON , June 23, 2016 ... & Hematology Review, 2016;12(1):22-8 http://doi.org/10.17925/OHR.2016.12.01.22 ... Review , the peer-reviewed journal from touchONCOLOGY, ... the escalating cost of cancer care is placing ... a result of expensive biologic therapies. With the ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... new line of intelligent tools designed, tuned and optimized exclusively for Okuma CNC ... in Chicago. The result of a collaboration among several companies with expertise in ...
Breaking Biology Technology:
(Date:3/31/2016)... 2016   LegacyXChange, ... "Company") LegacyXChange is excited to release its ... to be launched online site for trading 100% guaranteed ... will also provide potential shareholders a sense of the ... an industry that is notorious for fraud. The video ...
(Date:3/23/2016)... March 23, 2016 ... Sicherheit Gesichts- und Stimmerkennung mit Passwörtern ... (NASDAQ: MESG ), ein führender Anbieter ... Unternehmen mit SpeechPro zusammenarbeitet, um erstmals dessen ... wird die Möglichkeit angeboten, im Rahmen mobiler ...
(Date:3/21/2016)... WAKEFIELD, Massachusetts , March 22, 2016 ... and facial recognition with passcodes for superior security ... MESG ), a leading provider of secure digital communications ... pilot their biometric technology and offer enterprise customers, particularly ... provide secure facial recognition and voice authentication within a ...
Breaking Biology News(10 mins):